(RTTNews) – Nurix Therapeutics Inc. (NRIX) presented positive clinical data from its ongoing Phase 1a/1b clinical trial of NX-5948, an orally bioavailable, brain-penetrant degrader of Burton’s tyrosine kinase or BTK, in patients with relapsed/refractory Waldenström’s macroglobulinemia or WM at the 12th International Workshop on Waldenstrom’s Macroglobulinemia or IWWM-12.
NX-5948 demonstrated robust clinical activity, with objective responses observed in seven of nine evaluable Waldenstrom’s patients (77.8%) in the ongoing Phase 1a/1b clinical trial. Additionally, two patients experienced stable disease (22.2%).
The responses are durable and deepen over time, with two patients remaining on treatment for over one year.
The company noted that the data support its decision to advance NX-5948 into the ongoing Phase 1b expansion cohort in patients who have previously received at least one prior line of therapy including a BTK inhibitor and patients presenting with Bing-Neel syndrome, a rare form of WM with central nervous system involvement where NX-5948’s ability to penetrate the brain may offer a distinct advantage.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Source : Nasdaq